Skin cancer in liver transplant recipients

Skin cancer is the most common malignancy arising in the posttransplantation setting. Multiple factors contribute to the high risk for cutaneous carcinoma in immunosuppressed organ‐transplant recipients. We review the phenomenon of skin cancer in solid‐organ transplant recipients and further delineate the problem in the context of liver transplantation. Skin cancer is a significant medical and surgical problem for organ‐transplant recipients. With prolonged allograft function and patient survival, the majority of solid‐organ transplant recipients will eventually develop skin cancer. Although squamous cell carcinoma is the most common cutaneous malignancy in this population, basal cell carcinoma, melanoma, and Kaposi's sarcoma, as well as uncommon skin malignancies, may occur. Highly susceptible patients may develop hundreds of squamous cell carcinomas, which may be life threatening. Management strategies focus on regular full‐skin and nodal examination, aggressive treatment of established malignancies, and prophylactic measures to reduce the risk for additional photodamage and malignant transformation. Skin cancer is a substantial cause of morbidity and even mortality among solid‐organ transplant recipients. As a byproduct of immunosuppression, liver transplant recipients experience a high incidence of skin cancer and should be educated and managed accordingly.

[1]  V. Bain,et al.  Update in liver transplantation. , 1999, Canadian family physician Medecin de famille canadien.

[2]  E. Cowen,et al.  Awareness of skin cancer by kidney transplant patients. , 1999, Journal of American Academy of Dermatology.

[3]  Murphy,et al.  Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low‐dose acitretin , 1999, The British journal of dermatology.

[4]  L. Dennis,et al.  Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. , 1999, Archives of dermatology.

[5]  T. Weinreich,et al.  Malignant Fibrous Histiocytoma and Atypical Fibroxanthoma in Renal Transplant Recipients , 1999, Dermatology.

[6]  M. Lagman,et al.  Cyclosporine induces cancer progression by a cell-autonomous mechanism , 1999, Nature.

[7]  S Hansen,et al.  Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. , 1999, Journal of the American Academy of Dermatology.

[8]  P. Fauchald,et al.  Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone? , 1999, Transplantation proceedings.

[9]  J. Reyes,et al.  Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. , 1998, Transplantation.

[10]  Z. Hagay,et al.  Tumor-preventive effects of the soluble p53 antigen on chemically-induced skin cancer in mice. , 1998, Anticancer research.

[11]  J. O'Connell,et al.  Epithelioid angiosarcoma arising in a surgically constructed arteriovenous fistula: a rare complication of chronic immunosuppression in the setting of renal transplantation. , 1998, The American journal of surgical pathology.

[12]  J. DiGiovanna.  Posttransplantation skin cancer: scope of the problem, management, and role for systemic retinoid chemoprevention. , 1998, Transplantation proceedings.

[13]  L. Dzubow,et al.  Merkel cell carcinoma in a stem cell transplant patient. , 1998, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[14]  R. Adamson,et al.  High incidence and clinical course of aggressive skin cancer in heart transplant patients: a single-center study. , 1998, Transplantation proceedings.

[15]  F. Aubin,et al.  CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. , 1998, Transplantation.

[16]  B. Dréno,et al.  Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens , 1998, The Lancet.

[17]  U. Neumann,et al.  De novo malignancies after liver transplantation using tacrolimus‐based protocols or cyclosporine‐based quadruple immunosuppression with an interleukin‐2 receptor antibody or antithymocyte globulin , 1997, Cancer.

[18]  D. V. van Thiel,et al.  Non-lymphoid cancer after liver transplantation. , 1997, Hepato-gastroenterology.

[19]  D. Di Landro,et al.  Two cases of Kaposi's sarcoma in renal and liver transplant recipients treated with interferon. , 1996, Clinical transplantation.

[20]  B. O'Sullivan,et al.  The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. , 1996, Transplantation.

[21]  S. Morgan,et al.  Fatal Merkel-cell tumour (cutaneous neuroendocrine carcinoma) complicating renal transplantation. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  Jean Kanitakis,et al.  Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. , 1995, Journal of the American Academy of Dermatology.

[23]  J. Hermans,et al.  Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Gal,et al.  Fulminant Kaposi’s Sarcoma After Orthotopic Liver Transplantation , 1995 .

[25]  Jean Kanitakis,et al.  Aggressive squamous cell carcinomas in organ transplant recipients. , 1995, Transplantation proceedings.

[26]  B. Nelson,et al.  The role of dermabrasion and chemical peels in the treatment of patients with xeroderma pigmentosum. , 1995, Journal of the American Academy of Dermatology.

[27]  G. Cameron,et al.  High sun protection factor sunscreens in the suppression of actinic neoplasia. , 1995, Archives of dermatology.

[28]  B. Charpentier,et al.  Incidence and type of malignancies occurring after renal transplantation in conventionally and in cyclosporine-treated recipients: single-center analysis of a 20-year period in 1600 patients. , 1995, Transplantation proceedings.

[29]  Robin Marks,et al.  An overview of skin cancers , 1995, Cancer.

[30]  A. Rhodes,et al.  Public education and cancer of the skin. What do people need to know about melanoma and nonmelanoma skin cancer? , 1995, Cancer.

[31]  I. Penn.  De novo tumors in pediatric organ transplant recipients. , 1994, Transplantation proceedings.

[32]  F. Claas,et al.  Relation between skin cancer, humoral responses to human papillomaviruses, and HLA class II molecules in renal transplant recipients. , 1993, Journal of immunology.

[33]  A. Sheil,et al.  De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. , 1993, Transplantation proceedings.

[34]  O. Larkö,et al.  No difference in skin cancer incidence with or without cyclosporine--a 5-year perspective. , 1992, Transplantation proceedings.

[35]  S. Shuster,et al.  Skin cancer after renal transplantation: the causal role of azathioprine. , 1992, Acta dermato-venereologica.

[36]  J. Vandenbroucke,et al.  Relation between skin cancer and HLA antigens in renal-transplant recipients. , 1991, The New England journal of medicine.

[37]  D. Goldberg,et al.  Mohs micrographic surgery. , 2012, Clinical privilege white paper.

[38]  E. Abel.  Cutaneous manifestations of immunosuppression in organ transplant recipients. , 1989, Journal of the American Academy of Dermatology.

[39]  W. Meikle,et al.  EFFECTS OF IMMUNOSUPPRESSIVE THERAPY ON THE INDUCTION OF SKIN TUMORS BY ULTRAVIOLET IRRADIATION IN HAIRLESS MICE , 1987, Transplantation.

[40]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[41]  P. Macdonald,et al.  Skin cancer in Australian heart transplant recipients. , 1999, Journal of the American Academy of Dermatology.

[42]  Joachim Mühling,et al.  Photodynamic therapy of primary nonmelanomatous skin tumours of the head and neck , 1999, Lasers in surgery and medicine.

[43]  A. Baum,et al.  Successful behavioral interventions to prevent cancer: the example of skin cancer. , 1998, Annual review of public health.

[44]  Jean Kanitakis,et al.  Skin Diseases After Organ Transplantation , 1998 .

[45]  McGregor Jm,et al.  The role of papillomaviruses in human non-melanoma skin cancer. , 1996 .

[46]  N. Niranjan,et al.  Non-melanoma skin cancer in renal transplant recipients: the extent of the problem and a strategy for management. , 1994, British journal of plastic surgery.

[47]  I. Penn.  Occurrence of cancers in immunosuppressed organ transplant recipients. , 1994, Clinical transplants.

[48]  D. Dunn,et al.  De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. , 1994, Clinical transplantation.

[49]  J. Gibbs,et al.  De novo malignancy following liver transplantation: a single-center study. , 1993, Transplantation proceedings.

[50]  A. Sheil,et al.  Risk factors associated with the development of squamous cell carcinomas in immunosuppressed renal transplant recipients , 1992 .

[51]  E. Benton,et al.  The prevalence of skin disorders in renal allograft recipients receiving cyclosporin A compared with those receiving azathioprine. , 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.